EPHA10 and cancer: S5 Fig shows our evaluation of the anti-tumor effect of another dimeric BsAb (EphA10/CD3’) that was constructed with anti-CD3 IgM. Dimeric BsAb (EphA10/CD3’) did not show an anti-tumor effect because its affinity for CD3 was very low (The dissociation constant, KD≒10−7). Thus, the dimeric BsAb (EphA10/CD3) showed effectiveness against EphA10-positive cancer tumors in vivo only when bound to both EphA10 and CD3.